Relfydess® ▼ (RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology, developed and manufactured by Galderma.

Relfydess® is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines and lateral canthal lines.

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light. Unopened vial may be brought to room temperature at 25°C and protected from light. The stability of Relfydess (unopened vial) has been demonstrated for up to 24 hours at room temperature.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See ‘Undesirable Effects’ for how to report adverse reactions.

We provide Galderma (U.K.) Limited with certain information on who has purchased their products through this website for consumer service/support and safety purposes. A copy of Galderma’s Privacy Notice explaining how your data will be collected, used, and disclosed by Galderma can be found here https://tinyurl.com/galdermaprivacy

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, www.hpra.ie

Adverse events should also be reported to Galderma (UK) Ltd.

E-mail: Medinfo.uk@galderma.com Tel: +44 (0) 300 3035674